C.R. Bard Stock Price, News & Analysis (NYSE:BCR)

$334.50 2.40 (0.72 %)
(As of 12/18/2017 01:42 AM ET)
Previous Close$332.10
Today's Range$332.30 - $335.34
52-Week Range$218.72 - $337.73
Volume919,500 shs
Average Volume662,472 shs
Market Capitalization$24.38 billion
P/E Ratio28.89
Dividend Yield0.31%
Beta0.52

About C.R. Bard (NYSE:BCR)

C.R. Bard logoC. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive BCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BCR
CUSIP06738310
Phone908-277-8000

Debt

Debt-to-Equity Ratio0.57%
Current Ratio1.72%
Quick Ratio1.37%

Price-To-Earnings

Trailing P/E Ratio28.89
Forward P/E Ratio28.13
P/E Growth2.56

Sales & Book Value

Annual Sales$3.71 billion
Price / Sales6.56
Cash Flow$13.47 per share
Price / Cash24.83
Book Value$22.78 per share
Price / Book14.68

Profitability

Trailing EPS$7.59
Net Income$531.40 million
Net Margins14.75%
Return on Equity48.28%
Return on Assets16.23%

Miscellaneous

Employees16,300
Outstanding Shares72,890,000

C.R. Bard (NYSE:BCR) Frequently Asked Questions

What is C.R. Bard's stock symbol?

C.R. Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

How often does C.R. Bard pay dividends? What is the dividend yield for C.R. Bard?

C.R. Bard declared a quarterly dividend on Wednesday, October 11th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. View C.R. Bard's Dividend History.

How were C.R. Bard's earnings last quarter?

C.R. Bard, Inc. (NYSE:BCR) posted its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to analysts' expectations of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. C.R. Bard's quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. View C.R. Bard's Earnings History.

What guidance has C.R. Bard issued on next quarter's earnings?

C.R. Bard issued an update on its FY17 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $11.85-11.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.84.

Where is C.R. Bard's stock going? Where will C.R. Bard's stock price be in 2017?

7 brokerages have issued twelve-month price targets for C.R. Bard's stock. Their forecasts range from $255.00 to $337.00. On average, they expect C.R. Bard's stock price to reach $295.43 in the next year. View Analyst Ratings for C.R. Bard.

What are Wall Street analysts saying about C.R. Bard stock?

Here are some recent quotes from research analysts about C.R. Bard stock:

  • 1. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)
  • 2. According to Zacks Investment Research, "Over the past one year, C. R. Bard has outperformed the broader industry trends with respect to price performance. The company exhibited a solid second quarter of 2017, beating the Zacks Consensus on both lines. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth." (8/1/2017)

Who are some of C.R. Bard's key competitors?

Who are C.R. Bard's key executives?

C.R. Bard's management team includes the folowing people:

  • Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
  • John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
  • James C. Beasley, Group President (Age 53)
  • Timothy P. Collins, Group President (Age 56)
  • John P. Groetelaars, Group President (Age 50)
  • Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
  • Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
  • John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
  • Frank Lupisella Jr., Vice President, Controller (Age 56)
  • Betty D. Larson, Vice President - Human Resources (Age 41)

Who owns C.R. Bard stock?

C.R. Bard's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alpine Associates Management Inc. (1.27%), Wells Fargo & Company MN (1.06%), Bank of New York Mellon Corp (0.83%), Westchester Capital Management LLC (0.79%), Cowen Inc. (0.78%) and Magnetar Financial LLC (0.75%). Company insiders that own C.R. Bard stock include Anthony Welters, Betty D Larson, Christopher S Holland, David M Barrett, Frank Lupisella Jr, Frank Lupisella, Jr, Gail K Naughton, Jim C Beasley, John A Deford, John H Weiland, John P Groetelaars, Patricia G Christian, Sharon M Luboff, Timothy M Ring, Timothy P Collins, Tommy G Thompson and Tony L White. View Institutional Ownership Trends for C.R. Bard.

Who sold C.R. Bard stock? Who is selling C.R. Bard stock?

C.R. Bard's stock was sold by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, Neuberger Berman Group LLC, Bessemer Group Inc., Principal Financial Group Inc., Los Angeles Capital Management & Equity Research Inc., Davis R M Inc., Mackenzie Financial Corp and Gabelli Funds LLC. Company insiders that have sold C.R. Bard company stock in the last year include Betty D Larson, Christopher S Holland, David M Barrett, Frank Lupisella Jr, Frank Lupisella, Jr, Gail K Naughton, Jim C Beasley, John A Deford, John H Weiland, John P Groetelaars, Sharon M Luboff, Timothy M Ring and Timothy P Collins. View Insider Buying and Selling for C.R. Bard.

Who bought C.R. Bard stock? Who is buying C.R. Bard stock?

C.R. Bard's stock was acquired by a variety of institutional investors in the last quarter, including Cowen Inc., Wells Fargo & Company MN, Nuance Investments LLC, BNP Paribas Arbitrage SA, Canada Pension Plan Investment Board, Janus Henderson Group PLC, Alpine Associates Management Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for C.R. Bard.

How do I buy C.R. Bard stock?

Shares of C.R. Bard can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is C.R. Bard's stock price today?

One share of C.R. Bard stock can currently be purchased for approximately $334.50.

How big of a company is C.R. Bard?

C.R. Bard has a market capitalization of $24.38 billion and generates $3.71 billion in revenue each year. The medical instruments supplier earns $531.40 million in net income (profit) each year or $7.59 on an earnings per share basis. C.R. Bard employs 16,300 workers across the globe.

How can I contact C.R. Bard?

C.R. Bard's mailing address is 730 CENTRAL AVE, MURRAY HILL NJ, 07974. The medical instruments supplier can be reached via phone at 908-277-8000.


MarketBeat Community Rating for C.R. Bard (BCR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  480 (Vote Underperform)
Total Votes:  742
MarketBeat's community ratings are surveys of what our community members think about C.R. Bard and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

C.R. Bard (NYSE:BCR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.142.202.202.28
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $272.17$269.77$262.69$250.60
Price Target Upside: 18.51% downside19.23% downside17.99% downside17.43% downside

C.R. Bard (NYSE:BCR) Consensus Price Target History

Price Target History for C.R. Bard (NYSE:BCR)

C.R. Bard (NYSE:BCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017BarclaysBoost Price TargetEqual Weight$245.00 -> $337.00N/AView Rating Details
11/3/2017CowenReiterated RatingHold$317.00N/AView Rating Details
10/26/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
9/14/2017Jefferies GroupReiterated RatingHold$317.00MediumView Rating Details
7/11/2017BMO Capital MarketsReiterated RatingHold$317.00LowView Rating Details
4/26/2017Raymond James FinancialDowngradeStrong-Buy -> Mkt PerformLowView Rating Details
4/25/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformLowView Rating Details
4/24/2017Morgan StanleyDowngradeOverweight -> Equal WeightLowView Rating Details
1/27/2017JMP SecuritiesBoost Price Target$240.00 -> $255.00N/AView Rating Details
9/15/2016Evercore ISIInitiated CoverageBuy$235.00N/AView Rating Details
7/28/2016Leerink SwannReiterated RatingMarket Perform$240.00 -> $233.00N/AView Rating Details
7/27/2016J P Morgan Chase & CoBoost Price TargetNeutral$214.00 -> $225.00N/AView Rating Details
7/27/2016CitigroupBoost Price TargetBuy$241.00 -> $265.00N/AView Rating Details
7/27/2016Deutsche BankBoost Price TargetHold$234.00 -> $240.00N/AView Rating Details
7/8/2016Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
5/24/2016Piper Jaffray CompaniesReiterated RatingBuy$241.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageNeutral$205.00N/AView Rating Details
1/29/2016Goldman Sachs GroupLower Price TargetBuy$214.00 -> $211.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

C.R. Bard (NYSE:BCR) Earnings History and Estimates Chart

Earnings by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard (NYSE BCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017Q3 2017$2.96$3.02$990.64 million$989.80 millionViewN/AView Earnings Details
7/27/2017Q2 2017$2.84$2.92$976.53 million$979.70 millionViewN/AView Earnings Details
4/23/2017Q1 2017$2.65$2.87$916.15 million$938.80 millionViewN/AView Earnings Details
1/26/2017Q416$2.74$2.77$956.12 million$967.10 millionViewListenView Earnings Details
10/25/2016Q3$2.55$2.64$931.66 million$941.90 millionViewListenView Earnings Details
7/26/2016Q2$2.47$2.54$915.22 million$931.50 millionViewListenView Earnings Details
4/27/2016Q116$2.17$2.34$845.77 million$873.50 millionViewListenView Earnings Details
1/28/2016Q415$2.41$2.43$867.22 million$870.80 millionViewListenView Earnings Details
10/22/2015Q3$2.24$2.28$852.93 million$865.70 millionViewListenView Earnings Details
7/23/2015Q2$2.18$2.27$836.18 million$859.80 millionViewListenView Earnings Details
4/23/2015Q115$2.07$2.10$813.36 million$819.70 millionViewListenView Earnings Details
1/29/2015Q414$2.24$2.29$855.11 million$867.20 millionViewListenView Earnings Details
10/22/2014Q314$2.10$2.15$819.20 million$830.00 millionViewListenView Earnings Details
7/24/2014Q214$2.00$2.06$814.58 million$827.10 millionViewListenView Earnings Details
4/22/2014Q114$1.86$1.91$787.10 million$799.30 millionViewListenView Earnings Details
1/30/2014Q413$1.41$1.42$782.28 million$791.30 millionViewListenView Earnings Details
10/22/2013Q313$1.40$1.50$739.12 million$758.00 millionViewListenView Earnings Details
7/23/2013Q2 2013$1.38$1.42$750.91 million$759.90 millionViewListenView Earnings Details
4/23/2013Q1 2013$1.42$1.44$728.45 million$740.30 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.67$1.70$757.49 million$762.60 millionViewListenView Earnings Details
10/23/2012$1.64$1.64ViewN/AView Earnings Details
7/25/2012$1.64$1.62ViewN/AView Earnings Details
1/31/2012$1.68$1.70ViewN/AView Earnings Details
10/25/2011$1.60$1.62ViewN/AView Earnings Details
7/21/2011$1.57$1.57ViewN/AView Earnings Details
4/21/2011$1.46$1.51ViewN/AView Earnings Details
1/31/2011$1.48$1.54ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

C.R. Bard (NYSE:BCR) Earnings Estimates

2017 EPS Consensus Estimate: $11.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.56$2.64$2.61
Q2 20173$2.80$2.82$2.81
Q3 20173$2.89$3.02$2.96
Q4 20173$2.99$3.15$3.09
Q1 20181$2.88$2.88$2.88
Q2 20181$3.12$3.12$3.12
Q3 20181$3.19$3.19$3.19
(Data provided by Zacks Investment Research)

Dividends

C.R. Bard (NYSE:BCR) Dividend Information

Next Dividend:12/29/2017
Annual Dividend:$1.04
Dividend Yield:0.31%
Dividend Growth:6.80% (3 Year Average)
Payout Ratio:13.70% (Trailing 12 Months of Earnings)
8.75% (Based on This Year's Estimates)
8.01% (Based on Next Year's Estimates)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard (NYSE:BCR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/11/2017quarterly$0.260.32%12/7/201712/8/201712/29/2017
6/14/2017quarterly$0.260.33%7/20/20177/24/20178/4/2017
4/19/2017quarterly$0.260.41%4/27/20175/1/20175/12/2017
12/14/2016quarterly$0.260.47%1/19/20171/23/20172/3/2017
10/12/2016quarterly$0.260.48%10/20/201610/24/201611/4/2016
6/8/2016quarterly$0.260.46%7/14/20167/18/20167/29/2016
4/20/2016quarterly$0.240.46%4/28/20165/2/20165/13/2016
12/9/2015quarterly$0.240.52%1/21/20161/25/20162/5/2016
10/14/2015quarterly$0.240.5%10/22/201510/26/201511/6/2015
6/10/2015quarterly$0.240.56%7/16/20157/20/20157/31/2015
4/15/2015quarterly$0.220.52%4/23/20154/27/20155/8/2015
12/10/2014quarterly$0.220.52%1/22/20151/26/20152/6/2015
10/8/2014quarterly$0.220.59%10/16/201410/20/201410/31/2014
6/11/2014quarterly$0.220.62%7/17/20147/21/20148/1/2014
4/16/2014quarterly$0.210.6%4/24/20144/28/20145/9/2014
12/11/2013quarterly$0.210.63%1/16/20141/21/20141/31/2014
10/9/2013quarterly$0.210.72%10/17/201310/21/201311/1/2013
6/12/2013quarterly$0.210.77%7/18/20137/22/20138/2/2013
4/17/2013quarterly$0.200.8%4/25/20134/29/20135/10/2013
12/12/2012quarterly$0.200.83%1/17/20131/22/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

C.R. Bard (NYSE BCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 79.35%
Insider Trades by Quarter for C.R. Bard (NYSE:BCR)
Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard (NYSE BCR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/11/2017Jim C BeasleyInsiderSell15,044$332.00$4,994,608.00View SEC Filing  
11/7/2017John H WeilandVice ChairmanSell33,435$333.31$11,144,219.85View SEC Filing  
11/2/2017Christopher S. HollandInsiderSell38,242$334.04$12,774,357.68View SEC Filing  
11/2/2017Frank Lupisella JrVPSell7,035$334.70$2,354,614.50View SEC Filing  
10/30/2017David M. BarrettDirectorSell3,344$327.31$1,094,524.64View SEC Filing  
10/20/2017Betty D LarsonVPSell5,906$330.16$1,949,924.96View SEC Filing  
10/18/2017Frank Lupisella, Jr.VPSell9,173$325.00$2,981,225.00View SEC Filing  
10/12/2017Timothy P CollinsInsiderSell55,818$322.03$17,975,070.54View SEC Filing  
10/9/2017Timothy P CollinsInsiderSell8,388$322.00$2,700,936.00View SEC Filing  
9/29/2017Sharon M. LuboffInsiderSell30,252$320.00$9,680,640.00View SEC Filing  
8/10/2017John P GroetelaarsInsiderSell23,687$318.73$7,549,757.51View SEC Filing  
4/24/2017Frank Lupisella JrVPSell3,622$304.00$1,101,088.00View SEC Filing  
2/21/2017Jim C BeasleyInsiderSell4,390$245.00$1,075,550.00View SEC Filing  
2/14/2017John A DefordVPSell2,788$240.51$670,541.88View SEC Filing  
2/14/2017John H WeilandVice ChairmanSell14,091$240.49$3,388,744.59View SEC Filing  
2/14/2017John P GroetelaarsInsiderSell732$240.49$176,038.68View SEC Filing  
2/14/2017Timothy M RingChairmanSell14,425$240.50$3,469,212.50View SEC Filing  
2/13/2017John A. DefordVPSell469$240.07$112,592.83View SEC Filing  
2/13/2017John H WeilandVice ChairmanSell1,274$240.00$305,760.00View SEC Filing  
2/13/2017Timothy M RingChairmanSell1,767$240.02$424,115.34View SEC Filing  
2/13/2017Timothy P CollinsInsiderSell642$240.30$154,272.60View SEC Filing  
2/10/2017Betty D LarsonVPSell3,292$240.92$793,108.64View SEC Filing  
2/9/2017Jim C BeasleyInsiderSell8,593$239.58$2,058,710.94View SEC Filing  
2/9/2017John A. DefordVPSell5,816$239.58$1,393,397.28View SEC Filing  
2/9/2017John H WeilandVice ChairmanSell14,281$239.54$3,420,870.74View SEC Filing  
2/9/2017Timothy M RingChairmanSell20,324$239.56$4,868,817.44View SEC Filing  
1/31/2017Gail K NaughtonDirectorSell367$236.22$86,692.74View SEC Filing  
1/11/2017John P GroetelaarsInsiderSell573$235.00$134,655.00View SEC Filing  
1/10/2017Frank Lupisella, Jr.VPSell2,945$232.00$683,240.00View SEC Filing  
1/9/2017Frank Lupisella, Jr.VPSell210$232.00$48,720.00View SEC Filing  
12/30/2016Frank Lupisella JrVPSell237$226.00$53,562.00View SEC Filing  
12/30/2016Jim C BeasleyInsiderSell4,709$225.00$1,059,525.00View SEC Filing  
12/12/2016John A. DefordVPSell15,883$218.03$3,462,970.49View SEC Filing  
12/12/2016John H WeilandVice ChairmanSell11,190$219.67$2,458,107.30View SEC Filing  
12/12/2016Sharon M. LuboffInsiderSell6,000$219.00$1,314,000.00View SEC Filing  
10/28/2016Christopher S. HollandInsiderSell5,724$211.12$1,208,450.88View SEC Filing  
9/28/2016Timothy M RingChairmanSell92,293$227.81$21,025,268.33View SEC Filing  
9/26/2016Timothy M RingChairmanSell110,000$228.96$25,185,600.00View SEC Filing  
9/19/2016Betty D LarsonVPSell4,032$225.33$908,530.56View SEC Filing  
9/6/2016John A. DefordVPSell7,928$221.06$1,752,563.68View SEC Filing  
5/27/2016Christopher S HollandCFOSell3,970$219.89$872,963.30View SEC Filing  
5/17/2016John P GroetelaarsInsiderSell1,162$219.88$255,500.56View SEC Filing  
5/12/2016Tommy G ThompsonDirectorSell500$219.52$109,760.00View SEC Filing  
5/5/2016Tony L WhiteDirectorSell1,200$216.19$259,428.00View SEC Filing  
4/28/2016Jim C BeasleyInsiderSell4,709$215.00$1,012,435.00View SEC Filing  
4/27/2016Sharon M LuboffVPSell10,000$210.00$2,100,000.00View SEC Filing  
3/29/2016Christopher S HollandCFOSell1,650$200.00$330,000.00View SEC Filing  
2/25/2016Jim C BeasleyInsiderSell1,113$195.27$217,335.51View SEC Filing  
2/23/2016Frank Lupisella JrVPSell2,300$190.25$437,575.00View SEC Filing  
2/22/2016Christopher S HollandCFOSell618$190.00$117,420.00View SEC Filing  
2/22/2016Patricia G ChristianVPSell3,182$190.00$604,580.00View SEC Filing  
2/17/2016John A. DefordVPSell661$187.44$123,897.84View SEC Filing  
2/17/2016John H. WeilandCOOSell1,618$187.45$303,294.10View SEC Filing  
2/17/2016Timothy M. RingCEOSell2,453$187.62$460,231.86View SEC Filing  
2/17/2016Timothy P. CollinsinsiderSell974$187.48$182,605.52View SEC Filing  
2/16/2016Anthony WeltersDirectorSell1,784$187.47$334,446.48View SEC Filing  
2/12/2016Christopher S. HollandCFOSell6,297$181.08$1,140,260.76View SEC Filing  
2/12/2016John A. DefordVPSell6,400$182.40$1,167,360.00View SEC Filing  
2/12/2016John H. WeilandCOOSell15,632$182.86$2,858,467.52View SEC Filing  
2/12/2016Timothy M. RingCEOSell24,003$182.76$4,386,788.28View SEC Filing  
2/12/2016Timothy P. CollinsinsiderSell7,893$182.28$1,438,736.04View SEC Filing  
2/10/2016John P. GroetelaarsinsiderSell3,319$187.16$621,184.04View SEC Filing  
2/9/2016John A. DefordVPSell3,407$180.62$615,372.34View SEC Filing  
2/9/2016John H. WeilandCOOSell8,898$181.10$1,611,427.80View SEC Filing  
2/9/2016Timothy M. RingCEOSell4,836$181.20$876,283.20View SEC Filing  
2/9/2016Timothy P. CollinsinsiderSell4,205$181.24$762,114.20View SEC Filing  
2/2/2016Tommy G ThompsonDirectorSell2,319$188.75$437,711.25View SEC Filing  
12/16/2015John H. WeilandCOOSell19,686$188.49$3,710,614.14View SEC Filing  
12/16/2015Patricia G ChristianVPSell1,908$190.00$362,520.00View SEC Filing  
12/14/2015Jim C. BeasleyinsiderSell20,577$184.78$3,802,218.06View SEC Filing  
12/14/2015John A. DefordVPSell5,627$184.00$1,035,368.00View SEC Filing  
12/14/2015John H. WeilandCOOSell33,569$184.25$6,185,088.25View SEC Filing  
11/30/2015Timothy M. RingCEOSell22,052$187.37$4,131,883.24View SEC Filing  
10/29/2015Timothy M. RingCEOSell30,543$184.79$5,644,040.97View SEC Filing  
10/27/2015Gail K. NaughtonDirectorSell2,458$181.99$447,331.42View SEC Filing  
9/29/2015Timothy M. RingCEOSell40,000$185.16$7,406,400.00View SEC Filing  
8/31/2015Timothy M. RingCEOSell40,000$195.17$7,806,800.00View SEC Filing  
8/18/2015Sharon M. LuboffVPSell2,374$199.76$474,230.24View SEC Filing  
8/17/2015Sharon M LuboffVPSell2,030$200.00$406,000.00View SEC Filing  
8/14/2015Tommy G ThompsonDirectorSell1,200$199.25$239,100.00View SEC Filing  
7/13/2015John P GroetelaarsInsiderSell2,456$175.00$429,800.00View SEC Filing  
7/13/2015Timothy M RingCEOSell20,000$176.04$3,520,800.00View SEC Filing  
4/28/2015Tommy G ThompsonDirectorSell1,200$170.43$204,516.00View SEC Filing  
3/23/2015Timothy M RingCEOSell7,628$170.65$1,301,718.20View SEC Filing  
2/23/2015Timothy M RingCEOSell20,000$176.33$3,526,600.00View SEC Filing  
2/19/2015Jim C BeasleyInsiderSell2,884$174.79$504,094.36View SEC Filing  
2/19/2015John H WeilandCOOSell8,413$174.99$1,472,190.87View SEC Filing  
2/19/2015John P GroetelaarsVPSell4,566$175.14$799,689.24View SEC Filing  
2/17/2015Jim C BeasleyInsiderSell9,904$174.58$1,729,040.32View SEC Filing  
2/17/2015John A DefordVPSell6,146$174.58$1,072,968.68View SEC Filing  
2/17/2015John H WeilandCOOSell13,616$174.51$2,376,128.16View SEC Filing  
2/17/2015Timothy M RingCEOSell6,284$174.75$1,098,129.00View SEC Filing  
2/12/2015Patricia G ChristianVPSell1,408$173.97$244,949.76View SEC Filing  
2/12/2015Timothy M RingCEOSell14,363$173.74$2,495,427.62View SEC Filing  
2/12/2015Timothy P CollinsInsiderSell6,564$174.00$1,142,136.00View SEC Filing  
2/9/2015Anthony WeltersDirectorSell1,563$169.02$264,178.26View SEC Filing  
1/22/2015Timothy M RingCEOSell20,000$177.84$3,556,800.00View SEC Filing  
12/22/2014Timothy M RingCEOSell32,325$169.64$5,483,613.00View SEC Filing  
12/17/2014Jim C BeasleyInsiderSell4,525$168.42$762,100.50View SEC Filing  
12/17/2014Sharon M LuboffVPSell3,564$168.36$600,035.04View SEC Filing  
12/16/2014Jim C BeasleyInsiderSell14,634$167.47$2,450,755.98View SEC Filing  
12/16/2014John A DefordVPSell5,626$167.47$942,186.22View SEC Filing  
12/16/2014John H WeilandCOOSell23,093$166.74$3,850,526.82View SEC Filing  
12/16/2014Timothy M RingCEOSell15,232$166.60$2,537,651.20View SEC Filing  
12/15/2014John H WeilandCOOSell13,589$166.56$2,263,383.84View SEC Filing  
12/10/2014Patricia G ChristianVPSell1,269$169.20$214,714.80View SEC Filing  
12/9/2014John H WeilandCOOSell6,350$170.32$1,081,532.00View SEC Filing  
12/9/2014Timothy M RingCEOSell9,550$170.20$1,625,410.00View SEC Filing  
10/27/2014Sharon M LuboffVPSell10,000$158.80$1,588,000.00View SEC Filing  
10/22/2014Timothy M RingCEOSell60,000$149.07$8,944,200.00View SEC Filing  
10/6/2014Timothy M RingCEOSell60,000$148.00$8,880,000.00View SEC Filing  
9/10/2014John H WeilandCOOSell27,179$149.50$4,063,260.50View SEC Filing  
9/2/2014Timothy M RingCEOSell10,228$148.83$1,522,233.24View SEC Filing  
8/4/2014Bronwen K KellyVPSell10,055$150.25$1,510,763.75View SEC Filing  
8/1/2014Timothy M RingCEOSell10,231$149.04$1,524,828.24View SEC Filing  
7/30/2014Timothy P CollinsInsiderSell30,914$150.38$4,648,847.32View SEC Filing  
7/29/2014Sharon M LuboffVPSell5,115$151.37$774,257.55View SEC Filing  
7/1/2014Timothy M RingCEOSell10,231$144.30$1,476,333.30View SEC Filing  
6/2/2014Timothy M RingCEOSell10,231$147.50$1,509,072.50View SEC Filing  
3/3/2014Timothy RingCEOSell10,231$142.23$1,455,155.13View SEC Filing  
2/27/2014Sharon LuboffVPSell9,914$144.86$1,436,142.04View SEC Filing  
2/20/2014Frank Lupisella, Jr.VPSell2,520$140.26$353,455.20View SEC Filing  
2/18/2014Marc BreslawskyDirectorSell2,400$141.34$339,216.00View SEC Filing  
2/11/2014John WeilandCOOSell9,328$135.32$1,262,264.96View SEC Filing  
2/11/2014Sharon LuboffVPSell1,400$135.00$189,000.00View SEC Filing  
1/16/2014John WeilandCOOSell81,500$136.13$11,094,595.00View SEC Filing  
1/13/2014Sharon LuboffVPSell2,500$135.00$337,500.00View SEC Filing  
12/12/2013Jim BeasleyInsiderSell9,802$133.98$1,313,271.96View SEC Filing  
12/12/2013John DefordVPSell2,792$133.98$374,072.16View SEC Filing  
12/10/2013John WeilandCOOSell10,389$137.30$1,426,409.70View SEC Filing  
12/10/2013Timothy RingCEOSell15,623$137.12$2,142,225.76View SEC Filing  
12/2/2013Timothy RingCEOSell10,231$138.85$1,420,574.35View SEC Filing  
11/6/2013David BarrettDirectorSell1,600$138.13$221,008.00View SEC Filing  
10/28/2013Herbert L HenkelDirectorSell2,400$134.66$323,184.00View SEC Filing  
10/28/2013Sharon M AlterioVPSell14,002$134.91$1,889,009.82View SEC Filing  
10/23/2013John H WeilandCOOSell60,210$134.01$8,068,742.10View SEC Filing  
10/21/2013John H WeilandCOOSell84,525$125.62$10,618,030.50View SEC Filing  
10/21/2013Timothy M RingCEOSell8,313$125.52$1,043,447.76View SEC Filing  
10/18/2013Gary D DolchVPSell10,000$125.00$1,250,000.00View SEC Filing  
9/24/2013Timothy RingCEOSell8,313$117.77$979,022.01View SEC Filing  
9/9/2013John A DefordVPSell28,364$117.89$3,343,831.96View SEC Filing  
9/3/2013Timothy RingCEOSell10,231$114.65$1,172,984.15View SEC Filing  
8/30/2013Jim BeasleyInsiderSell1,420$115.33$163,768.60View SEC Filing  
8/21/2013Timothy RingCEOSell8,313$113.24$941,364.12View SEC Filing  
8/12/2013Sharon AlterioVPSell13,379$117.01$1,565,476.79View SEC Filing  
8/5/2013Brian P KellyVPSell28,000$115.69$3,239,320.00View SEC Filing  
8/2/2013David M BarrettDirectorSell1,200$115.70$138,840.00View SEC Filing  
8/2/2013Frank Lupisella JrVPSell10,500$115.61$1,213,905.00View SEC Filing  
8/1/2013John H WeilandCOOSell87,336$115.35$10,074,207.60View SEC Filing  
7/29/2013Timothy P CollinsInsiderSell22,025$113.60$2,502,040.00View SEC Filing  
7/26/2013Anthony WeltersDirectorSell5,600$113.12$633,472.00View SEC Filing  
7/26/2013Jean F HollowayVPSell2,275$113.52$258,258.00View SEC Filing  
7/22/2013Timothy M RingCEOSell8,312$113.58$944,076.96View SEC Filing  
6/21/2013Timothy M RingCEOSell8,312$110.05$914,735.60View SEC Filing  
6/20/2013Gary D DolchVPSell14,569$109.97$1,602,152.93View SEC Filing  
5/21/2013Timothy M RingCEOSell8,312$106.65$886,474.80View SEC Filing  
5/20/2013Marc C BreslawskyDirectorSell2,400$107.20$257,280.00View SEC Filing  
5/8/2013Timothy M RingCEOSell8,312$102.00$847,824.00View SEC Filing  
4/11/2013G Mason MorfitInsiderSell300,000$102.47$30,741,000.00View SEC Filing  
4/9/2013Timothy M RingCEOSell8,312$102.00$847,824.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

C.R. Bard (NYSE BCR) News Headlines

Source:
DateHeadline
C.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in StockC.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in Stock
www.americanbankingnews.com - December 13 at 5:26 PM
C.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 BillionC.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 Billion
www.americanbankingnews.com - December 13 at 12:34 PM
Zacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per ShareZacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per Share
www.americanbankingnews.com - December 11 at 1:24 AM
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017
finance.yahoo.com - December 8 at 11:30 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017
finance.yahoo.com - December 7 at 3:53 PM
C.R. Bard (BCR) Downgraded to "Hold" at ValuEngineC.R. Bard (BCR) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 3 at 10:04 PM
How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?
finance.yahoo.com - December 3 at 3:46 PM
Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN)Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN)
www.americanbankingnews.com - December 2 at 11:28 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017
finance.yahoo.com - November 27 at 5:12 PM
C.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from AnalystsC.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 12:34 PM
Paul Tudor Jones: The Global Macro TraderPaul Tudor Jones: The Global Macro Trader
finance.yahoo.com - November 25 at 3:37 PM
 Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion
www.americanbankingnews.com - November 25 at 9:44 AM
C.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per ShareC.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per Share
www.americanbankingnews.com - November 23 at 3:10 AM
CR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.comCR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.com
investorplace.com - November 21 at 4:56 PM
CR Bard (BCR) a Strong Buy on Outstanding Quant ScoreCR Bard (BCR) a Strong Buy on Outstanding Quant Score
investorplace.com - November 21 at 12:06 PM
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product LinesBD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
finance.yahoo.com - November 16 at 11:54 AM
See what the IHS Markit Score report has to say about C R Bard Inc.See what the IHS Markit Score report has to say about C R Bard Inc.
finance.yahoo.com - November 15 at 3:02 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 13, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 13, 2017
finance.yahoo.com - November 14 at 1:33 AM
Critical Survey: C.R. Bard (BCR) & Transenterix (TRXC)Critical Survey: C.R. Bard (BCR) & Transenterix (TRXC)
www.americanbankingnews.com - November 12 at 1:10 AM
CR Bard (BCR) a Strong Buy on Top-End Quant Score - Investorplace.comCR Bard (BCR) a Strong Buy on Top-End Quant Score - Investorplace.com
investorplace.com - November 9 at 5:36 PM
John H. Weiland Sells 33,435 Shares of C.R. Bard, Inc. (BCR) StockJohn H. Weiland Sells 33,435 Shares of C.R. Bard, Inc. (BCR) Stock
www.americanbankingnews.com - November 9 at 3:30 PM
CR Bard (BCR) a Strong Buy on Top-End Quant ScoreCR Bard (BCR) a Strong Buy on Top-End Quant Score
investorplace.com - November 7 at 3:34 PM
C.R. Bard, Inc. (BCR) Price Target Raised to $337.00 at Barclays PLCC.R. Bard, Inc. (BCR) Price Target Raised to $337.00 at Barclays PLC
www.americanbankingnews.com - November 6 at 9:43 PM
C.R. Bard, Inc. (BCR) VP Sells $2,354,614.50 in StockC.R. Bard, Inc. (BCR) VP Sells $2,354,614.50 in Stock
www.americanbankingnews.com - November 6 at 9:20 PM
C.R. Bard, Inc. (BCR) Insider Christopher S. Holland Sells 38,242 SharesC.R. Bard, Inc. (BCR) Insider Christopher S. Holland Sells 38,242 Shares
www.americanbankingnews.com - November 6 at 9:20 PM
Corporate News Blog - Medical Technology Company Pulse Biosciences Announces Changes to its BoardCorporate News Blog - Medical Technology Company Pulse Biosciences Announces Changes to its Board
finance.yahoo.com - November 6 at 5:28 PM
C R Bard Inc (BCR) Expected to Announce Earnings of $3.12 Per ShareC R Bard Inc (BCR) Expected to Announce Earnings of $3.12 Per Share
www.americanbankingnews.com - November 4 at 1:18 AM
Cowen and Company Reaffirms "Hold" Rating for C.R. Bard, Inc. (BCR)Cowen and Company Reaffirms "Hold" Rating for C.R. Bard, Inc. (BCR)
www.americanbankingnews.com - November 3 at 7:50 PM
C.R. Bard, Inc. (BCR) Given Consensus Recommendation of "Hold" by AnalystsC.R. Bard, Inc. (BCR) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 2 at 3:28 PM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 1, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 1, 2017
finance.yahoo.com - November 1 at 5:02 PM
C.R. Bard, Inc. (BCR) Director Sells $1,094,524.64 in StockC.R. Bard, Inc. (BCR) Director Sells $1,094,524.64 in Stock
www.americanbankingnews.com - October 31 at 5:40 PM
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017
finance.yahoo.com - October 30 at 5:27 PM
Head to Head Review: C.R. Bard (BCR) and Its CompetitorsHead to Head Review: C.R. Bard (BCR) and Its Competitors
www.americanbankingnews.com - October 30 at 8:22 AM
C.R. Bard (BCR) vs. CONMED Corporation (CNMD) Critical SurveyC.R. Bard (BCR) vs. CONMED Corporation (CNMD) Critical Survey
www.americanbankingnews.com - October 27 at 9:20 PM
Head-To-Head Comparison: C.R. Bard (BCR) and STAAR Surgical (STAA)Head-To-Head Comparison: C.R. Bard (BCR) and STAAR Surgical (STAA)
www.americanbankingnews.com - October 27 at 11:48 AM
Needham & Company LLC Reiterates "Hold" Rating for C.R. Bard, Inc. (BCR)Needham & Company LLC Reiterates "Hold" Rating for C.R. Bard, Inc. (BCR)
www.americanbankingnews.com - October 26 at 7:38 AM
C.R. Bard, Inc. (BCR) Releases  Earnings Results, Beats Expectations By $0.06 EPSC.R. Bard, Inc. (BCR) Releases Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - October 25 at 10:04 PM
C. R. Bard Updates 2017 Guidance - Quick FactsC. R. Bard Updates 2017 Guidance - Quick Facts
www.nasdaq.com - October 25 at 5:46 PM
C.R. Bard Inc Q3 Income Rises 14%C.R. Bard Inc Q3 Income Rises 14%
www.rttnews.com - October 25 at 5:46 PM
Bard Announces Third Quarter ResultsBard Announces Third Quarter Results
finance.yahoo.com - October 25 at 5:46 PM
C.R. Bard beats 3Q profit forecastsC.R. Bard beats 3Q profit forecasts
finance.yahoo.com - October 25 at 5:46 PM
C.R. Bard, Inc. (BCR) Issues FY17 Earnings GuidanceC.R. Bard, Inc. (BCR) Issues FY17 Earnings Guidance
www.americanbankingnews.com - October 25 at 5:27 PM
C.R. Bard, Inc. (BCR) VP Sells $1,949,924.96 in StockC.R. Bard, Inc. (BCR) VP Sells $1,949,924.96 in Stock
www.americanbankingnews.com - October 24 at 1:28 PM
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings? - NasdaqEW vs. BCR: Which Stock is Poised for Better Q3 Earnings? - Nasdaq
www.nasdaq.com - October 23 at 10:24 PM
Research Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - October 23 at 5:22 PM
Frank Lupisella, Jr. Sells 9,173 Shares of C.R. Bard, Inc. (BCR) StockFrank Lupisella, Jr. Sells 9,173 Shares of C.R. Bard, Inc. (BCR) Stock
www.americanbankingnews.com - October 20 at 1:38 PM
Can CR Bard (BCR) Spring a Surprise This Earnings Season? - NasdaqCan CR Bard (BCR) Spring a Surprise This Earnings Season? - Nasdaq
www.nasdaq.com - October 18 at 5:45 PM
Contrasting C.R. Bard (BCR) & InspireMD (NSPR)Contrasting C.R. Bard (BCR) & InspireMD (NSPR)
www.americanbankingnews.com - October 18 at 10:34 AM
Can CR Bard (BCR) Spring a Surprise This Earnings Season?Can CR Bard (BCR) Spring a Surprise This Earnings Season?
finance.yahoo.com - October 17 at 5:16 PM
C.R. Bard, Inc. (BCR) Expected to Post Quarterly Sales of $989.81 MillionC.R. Bard, Inc. (BCR) Expected to Post Quarterly Sales of $989.81 Million
www.americanbankingnews.com - October 17 at 6:00 AM

SEC Filings

C.R. Bard (NYSE:BCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

C.R. Bard (NYSE:BCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

C.R. Bard (NYSE BCR) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.